SCHEMBL7752224

SCHEMBL7752224

O=C(O)CCc1oc2ccccc2c1C(=O)c1cc(I)c(O)c(I)c1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EYA3 Q99504 6/20 0.74
▸ TTR P02766 5/20 0.73
▸ MEN1 O00255 2/20 0.73
▸ ABCB11 O95342 2/20 0.73
▸ LMNA P02545 2/20 0.73
▸ PGR P06401 2/20 0.73
▸ ADRA2A P08913 2/20 0.73
▸ TBXA2R P21731 2/20 0.73
▸ OPRM1 P35372 2/20 0.73
▸ SLC6A3 Q01959 2/20 0.73
▸ KMT2A Q03164 2/20 0.73
▸ BIRC5 O15392 1/20 0.73
▸ HTR1A P08908 1/20 0.73
▸ DRD1 P21728 1/20 0.73
▸ PTGS1 P23219 1/20 0.73
▸ SLC6A2 P23975 1/20 0.73
▸ PDE4A P27815 1/20 0.73
▸ ADORA1 P30542 1/20 0.73
▸ DRD3 P35462 1/20 0.73
▸ HRH3 Q9Y5N1 1/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3119701 0.88 EYA3 (0.77) EYA3TTRMEN1ABCB11LMNA
SCHEMBL6335384 0.85 EYA3 (1.00) EYA3TTRMEN1ABCB11LMNA
SCHEMBL7101769 0.85 EYA3 (0.71) EYA3TTRMEN1ABCB11LMNA
Benziodarone SCHEMBL308541 0.85 EYA3 (1.00) EYA3TTRMEN1ABCB11LMNA
Benziodarone SCHEMBL31326233 0.85 EYA3 (1.00) EYA3TTRMEN1ABCB11LMNA
SCHEMBL25389973 0.84 EYA3 (0.85) EYA3TTRMEN1ABCB11LMNA
SCHEMBL25393114 0.84 EYA3 (0.73) EYA3TTRMEN1ABCB11LMNA
SCHEMBL25389746 0.84 EYA3 (0.73) EYA3TTRMEN1ABCB11LMNA
SCHEMBL6336681 0.84 EYA3 (0.75) EYA3TTRMEN1ABCB11LMNA
SCHEMBL25390721 0.83 EYA3 (0.91) EYA3TTRMEN1ABCB11LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6316487-B1 FOR THERAPY OF VENTRICULAR TACHYARRHYTHMIAS, ESPECIALLY IN PATIENTS WITH CONGESTIVE HEART FAILURE AND VENTRICULAR ARRHYTHMIAS AND SUPRAVENTRICULAR ARRHYTHMIAS, INCLUDING ATRIAL FIBRILLATION AND RE-ENTRANT TACHYARRHYTHMIAS ARYX THERAPEUTICS 2001-11-13 — — US disclosed
Send feedback